Cronos (CRON) Cash from Financing Activities (2019 - 2026)
Cronos' (CRON) quarterly Cash from Financing Activities came in at -$18.3 million in Q1 2026, down 523.48% year-on-year from $4.3 million in Q1 2025, and down 146.1% quarter-over-quarter from -$7.4 million in Q4 2025.
Cronos (CRON) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Cronos' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at -$18.3 million for Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 523.48% year-over-year to -$18.3 million in Q1 2026; TTM through Mar 2026 was -$35.2 million, a 902.36% decrease from a year earlier, with the FY2025 full-year figure at -$19.9 million, down 1516.98% from the prior year.
- Cash from Financing Activities fell to -$18.3 million in Q1 2026 per CRON's latest filing, from -$7.4 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at -$13000.0 in Q3 2024 and bottomed at -$18.3 million in Q1 2026.
- The 5-year median for Cash from Financing Activities is -$620000.0 (2022), against an average of -$2.5 million.
- Across the five-year window, Cash from Financing Activities surged 97.52% in 2023 and plunged 14253.85% in 2025, its largest moves.
- Year by year, Cash from Financing Activities stood at -$620000.0 in 2022, then soared by 64.84% to -$218000.0 in 2023, then slumped by 43.58% to -$313000.0 in 2024, then sank by 2271.57% to -$7.4 million in 2025, then tumbled by 146.1% to -$18.3 million in 2026.
- Per Business Quant, the three latest CRON Cash from Financing Activities figures stand at -$18.3 million (Q1 2026), -$7.4 million (Q4 2025), and -$1.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Cronos | 1.04 Bn | 267.78 Mn | 19.15 Mn | -18.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.27 Mn |
| Mar 31, 2026 | -18.27 Mn |
| Dec 31, 2025 | -7.42 Mn |
| Dec 31, 2025 | -7.42 Mn |
| Sep 30, 2025 | -1.87 Mn |
| Sep 30, 2025 | -1.87 Mn |
| Jun 30, 2025 | -7.69 Mn |
| Jun 30, 2025 | -7.69 Mn |
| Mar 31, 2025 | -2.93 Mn |
| Mar 31, 2025 | -2.93 Mn |
| Dec 31, 2024 | -313,000.00 |
| Dec 31, 2024 | -313,000.00 |
| Sep 30, 2024 | -13,000.00 |
| Sep 30, 2024 | -13,000.00 |
| Jun 30, 2024 | -260,000.00 |
| Jun 30, 2024 | -260,000.00 |
| Mar 31, 2024 | -645,000.00 |
| Mar 31, 2024 | -645,000.00 |
| Dec 31, 2023 | -218,000.00 |
| Dec 31, 2023 | -218,000.00 |